nodes	percent_of_prediction	percent_of_DWPC	metapath
Neostigmine—BCHE—diaphragm—chronic obstructive pulmonary disease	0.0438	0.638	CbGeAlD
Neostigmine—BCHE—respiratory system—chronic obstructive pulmonary disease	0.005	0.0728	CbGeAlD
Neostigmine—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.00434	0.00465	CcSEcCtD
Neostigmine—Arrhythmia—Tiotropium—chronic obstructive pulmonary disease	0.00432	0.00463	CcSEcCtD
Neostigmine—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.00431	0.00463	CcSEcCtD
Neostigmine—Drowsiness—Montelukast—chronic obstructive pulmonary disease	0.00425	0.00457	CcSEcCtD
Neostigmine—Mental disorder—Tiotropium—chronic obstructive pulmonary disease	0.00423	0.00454	CcSEcCtD
Neostigmine—BCHE—bronchus—chronic obstructive pulmonary disease	0.00411	0.0599	CbGeAlD
Neostigmine—Drowsiness—Salbutamol—chronic obstructive pulmonary disease	0.0041	0.0044	CcSEcCtD
Neostigmine—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.0041	0.0044	CcSEcCtD
Neostigmine—BCHE—smooth muscle tissue—chronic obstructive pulmonary disease	0.00403	0.0586	CbGeAlD
Neostigmine—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.00402	0.00432	CcSEcCtD
Neostigmine—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00392	0.0042	CcSEcCtD
Neostigmine—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.00386	0.00415	CcSEcCtD
Neostigmine—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.00385	0.00413	CcSEcCtD
Neostigmine—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.00385	0.00413	CcSEcCtD
Neostigmine—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.00383	0.00411	CcSEcCtD
Neostigmine—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.00383	0.00411	CcSEcCtD
Neostigmine—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.00382	0.0041	CcSEcCtD
Neostigmine—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.00382	0.0041	CcSEcCtD
Neostigmine—Syncope—Tiotropium—chronic obstructive pulmonary disease	0.00377	0.00405	CcSEcCtD
Neostigmine—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.00377	0.00405	CcSEcCtD
Neostigmine—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.00375	0.00403	CcSEcCtD
Neostigmine—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.00374	0.00402	CcSEcCtD
Neostigmine—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00373	0.00401	CcSEcCtD
Neostigmine—Loss of consciousness—Tiotropium—chronic obstructive pulmonary disease	0.0037	0.00397	CcSEcCtD
Neostigmine—BCHE—trachea—chronic obstructive pulmonary disease	0.00369	0.0538	CbGeAlD
Neostigmine—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.00364	0.00391	CcSEcCtD
Neostigmine—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.00364	0.0039	CcSEcCtD
Neostigmine—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.00362	0.00388	CcSEcCtD
Neostigmine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00361	0.00387	CcSEcCtD
Neostigmine—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.00361	0.00387	CcSEcCtD
Neostigmine—Shock—Aminophylline—chronic obstructive pulmonary disease	0.00358	0.00384	CcSEcCtD
Neostigmine—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.00358	0.00384	CcSEcCtD
Neostigmine—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.00357	0.00383	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00356	0.00382	CcSEcCtD
Neostigmine—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.00355	0.00381	CcSEcCtD
Neostigmine—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00351	0.00377	CcSEcCtD
Neostigmine—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00351	0.00377	CcSEcCtD
Neostigmine—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.0035	0.00376	CcSEcCtD
Neostigmine—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.00348	0.00374	CcSEcCtD
Neostigmine—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.00348	0.00374	CcSEcCtD
Neostigmine—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00347	0.00373	CcSEcCtD
Neostigmine—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00344	0.00369	CcSEcCtD
Neostigmine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00344	0.00369	CcSEcCtD
Neostigmine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00344	0.00369	CcSEcCtD
Neostigmine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00342	0.00367	CcSEcCtD
Neostigmine—Flushing—Salbutamol—chronic obstructive pulmonary disease	0.00342	0.00367	CcSEcCtD
Neostigmine—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.00342	0.00367	CcSEcCtD
Neostigmine—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.00342	0.00367	CcSEcCtD
Neostigmine—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.0034	0.00365	CcSEcCtD
Neostigmine—Shock—Tiotropium—chronic obstructive pulmonary disease	0.00338	0.00363	CcSEcCtD
Neostigmine—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00337	0.00361	CcSEcCtD
Neostigmine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.00335	0.0036	CcSEcCtD
Neostigmine—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.00335	0.00359	CcSEcCtD
Neostigmine—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00333	0.00358	CcSEcCtD
Neostigmine—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00332	0.00356	CcSEcCtD
Neostigmine—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.00329	0.00353	CcSEcCtD
Neostigmine—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.00329	0.00353	CcSEcCtD
Neostigmine—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.00326	0.0035	CcSEcCtD
Neostigmine—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.00326	0.0035	CcSEcCtD
Neostigmine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00324	0.00348	CcSEcCtD
Neostigmine—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.00322	0.00346	CcSEcCtD
Neostigmine—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.0032	0.00343	CcSEcCtD
Neostigmine—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.00316	0.00339	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.00313	0.00336	CcSEcCtD
Neostigmine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.00312	0.00335	CcSEcCtD
Neostigmine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.00312	0.00335	CcSEcCtD
Neostigmine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.0031	0.00333	CcSEcCtD
Neostigmine—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.00308	0.00331	CcSEcCtD
Neostigmine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.00305	0.00328	CcSEcCtD
Neostigmine—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.00305	0.00328	CcSEcCtD
Neostigmine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00298	0.0032	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00296	0.00318	CcSEcCtD
Neostigmine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.00294	0.00316	CcSEcCtD
Neostigmine—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.0029	0.00312	CcSEcCtD
Neostigmine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00289	0.0031	CcSEcCtD
Neostigmine—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.00289	0.0031	CcSEcCtD
Neostigmine—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.00289	0.0031	CcSEcCtD
Neostigmine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.00288	0.00309	CcSEcCtD
Neostigmine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00288	0.00309	CcSEcCtD
Neostigmine—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.00287	0.00309	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00287	0.00308	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00287	0.00308	CcSEcCtD
Neostigmine—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.00283	0.00304	CcSEcCtD
Neostigmine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00283	0.00303	CcSEcCtD
Neostigmine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00283	0.00303	CcSEcCtD
Neostigmine—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00282	0.00302	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00281	0.00302	CcSEcCtD
Neostigmine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00281	0.00301	CcSEcCtD
Neostigmine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.00277	0.00297	CcSEcCtD
Neostigmine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.00277	0.00297	CcSEcCtD
Neostigmine—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.00273	0.00293	CcSEcCtD
Neostigmine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.00273	0.00293	CcSEcCtD
Neostigmine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00272	0.00292	CcSEcCtD
Neostigmine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00272	0.00292	CcSEcCtD
Neostigmine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00271	0.00291	CcSEcCtD
Neostigmine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.00271	0.00291	CcSEcCtD
Neostigmine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.0027	0.0029	CcSEcCtD
Neostigmine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.0027	0.0029	CcSEcCtD
Neostigmine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00269	0.00289	CcSEcCtD
Neostigmine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00269	0.00289	CcSEcCtD
Neostigmine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00268	0.00288	CcSEcCtD
Neostigmine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00267	0.00286	CcSEcCtD
Neostigmine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00266	0.00286	CcSEcCtD
Neostigmine—BCHE—lung—chronic obstructive pulmonary disease	0.00265	0.0387	CbGeAlD
Neostigmine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00263	0.00283	CcSEcCtD
Neostigmine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00262	0.00281	CcSEcCtD
Neostigmine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.00259	0.00278	CcSEcCtD
Neostigmine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.00259	0.00278	CcSEcCtD
Neostigmine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00257	0.00276	CcSEcCtD
Neostigmine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.00257	0.00276	CcSEcCtD
Neostigmine—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.00257	0.00276	CcSEcCtD
Neostigmine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00256	0.00275	CcSEcCtD
Neostigmine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.00255	0.00274	CcSEcCtD
Neostigmine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00254	0.00273	CcSEcCtD
Neostigmine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00253	0.00271	CcSEcCtD
Neostigmine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.00253	0.00271	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.00252	0.00271	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00252	0.00271	CcSEcCtD
Neostigmine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.0025	0.00269	CcSEcCtD
Neostigmine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.0025	0.00269	CcSEcCtD
Neostigmine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00249	0.00267	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00247	0.00265	CcSEcCtD
Neostigmine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00247	0.00265	CcSEcCtD
Neostigmine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00247	0.00265	CcSEcCtD
Neostigmine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00246	0.00264	CcSEcCtD
Neostigmine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00246	0.00264	CcSEcCtD
Neostigmine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00245	0.00263	CcSEcCtD
Neostigmine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.00244	0.00262	CcSEcCtD
Neostigmine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00243	0.00261	CcSEcCtD
Neostigmine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00241	0.00259	CcSEcCtD
Neostigmine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00241	0.00258	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00239	0.00257	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00239	0.00257	CcSEcCtD
Neostigmine—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.00238	0.0347	CbGeAlD
Neostigmine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00238	0.00256	CcSEcCtD
Neostigmine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00237	0.00254	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00234	0.00251	CcSEcCtD
Neostigmine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00233	0.0025	CcSEcCtD
Neostigmine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00232	0.0025	CcSEcCtD
Neostigmine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00231	0.00248	CcSEcCtD
Neostigmine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00229	0.00246	CcSEcCtD
Neostigmine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00229	0.00246	CcSEcCtD
Neostigmine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00228	0.00245	CcSEcCtD
Neostigmine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00227	0.00244	CcSEcCtD
Neostigmine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00226	0.00243	CcSEcCtD
Neostigmine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00226	0.00243	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00226	0.00242	CcSEcCtD
Neostigmine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00222	0.00238	CcSEcCtD
Neostigmine—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.00222	0.00238	CcSEcCtD
Neostigmine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.0022	0.00236	CcSEcCtD
Neostigmine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.0022	0.00236	CcSEcCtD
Neostigmine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00219	0.00235	CcSEcCtD
Neostigmine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00219	0.00235	CcSEcCtD
Neostigmine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00218	0.00234	CcSEcCtD
Neostigmine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00216	0.00232	CcSEcCtD
Neostigmine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00216	0.00232	CcSEcCtD
Neostigmine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00216	0.00232	CcSEcCtD
Neostigmine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.00216	0.00231	CcSEcCtD
Neostigmine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00215	0.00231	CcSEcCtD
Neostigmine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.00215	0.00231	CcSEcCtD
Neostigmine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00214	0.0023	CcSEcCtD
Neostigmine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00214	0.0023	CcSEcCtD
Neostigmine—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.00211	0.00226	CcSEcCtD
Neostigmine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.00208	0.00223	CcSEcCtD
Neostigmine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00207	0.00222	CcSEcCtD
Neostigmine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00204	0.00219	CcSEcCtD
Neostigmine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00204	0.00219	CcSEcCtD
Neostigmine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00204	0.00219	CcSEcCtD
Neostigmine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.002	0.00215	CcSEcCtD
Neostigmine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00199	0.00213	CcSEcCtD
Neostigmine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00199	0.00213	CcSEcCtD
Neostigmine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00196	0.0021	CcSEcCtD
Neostigmine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00196	0.0021	CcSEcCtD
Neostigmine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00195	0.00209	CcSEcCtD
Neostigmine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00193	0.00207	CcSEcCtD
Neostigmine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00192	0.00206	CcSEcCtD
Neostigmine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00189	0.00203	CcSEcCtD
Neostigmine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00189	0.00203	CcSEcCtD
Neostigmine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.00189	0.00203	CcSEcCtD
Neostigmine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.00188	0.00201	CcSEcCtD
Neostigmine—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.00187	0.002	CcSEcCtD
Neostigmine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00186	0.00199	CcSEcCtD
Neostigmine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00185	0.00199	CcSEcCtD
Neostigmine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00183	0.00197	CcSEcCtD
Neostigmine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00183	0.00197	CcSEcCtD
Neostigmine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00179	0.00193	CcSEcCtD
Neostigmine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.00179	0.00192	CcSEcCtD
Neostigmine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00176	0.00189	CcSEcCtD
Neostigmine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00176	0.00189	CcSEcCtD
Neostigmine—ABCB1—trachea—chronic obstructive pulmonary disease	0.00176	0.0256	CbGeAlD
Neostigmine—Rash—Formoterol—chronic obstructive pulmonary disease	0.00175	0.00188	CcSEcCtD
Neostigmine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00175	0.00188	CcSEcCtD
Neostigmine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00174	0.00187	CcSEcCtD
Neostigmine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00174	0.00187	CcSEcCtD
Neostigmine—Headache—Formoterol—chronic obstructive pulmonary disease	0.00174	0.00186	CcSEcCtD
Neostigmine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00174	0.00186	CcSEcCtD
Neostigmine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00173	0.00186	CcSEcCtD
Neostigmine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00172	0.00185	CcSEcCtD
Neostigmine—Rash—Montelukast—chronic obstructive pulmonary disease	0.00171	0.00184	CcSEcCtD
Neostigmine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00171	0.00183	CcSEcCtD
Neostigmine—Headache—Montelukast—chronic obstructive pulmonary disease	0.0017	0.00182	CcSEcCtD
Neostigmine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00166	0.00179	CcSEcCtD
Neostigmine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.00165	0.00177	CcSEcCtD
Neostigmine—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.00165	0.00177	CcSEcCtD
Neostigmine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00165	0.00177	CcSEcCtD
Neostigmine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00165	0.00177	CcSEcCtD
Neostigmine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00165	0.00177	CcSEcCtD
Neostigmine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00164	0.00176	CcSEcCtD
Neostigmine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.00162	0.00173	CcSEcCtD
Neostigmine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00161	0.00173	CcSEcCtD
Neostigmine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.00159	0.00171	CcSEcCtD
Neostigmine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.00156	0.00168	CcSEcCtD
Neostigmine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00155	0.00167	CcSEcCtD
Neostigmine—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.00151	0.00162	CcSEcCtD
Neostigmine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.0015	0.00161	CcSEcCtD
Neostigmine—Shock—Prednisolone—chronic obstructive pulmonary disease	0.00148	0.00158	CcSEcCtD
Neostigmine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.00146	0.00157	CcSEcCtD
Neostigmine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.00145	0.00156	CcSEcCtD
Neostigmine—Flushing—Prednisone—chronic obstructive pulmonary disease	0.00142	0.00153	CcSEcCtD
Neostigmine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.00137	0.00147	CcSEcCtD
Neostigmine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.00136	0.00146	CcSEcCtD
Neostigmine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.00134	0.00144	CcSEcCtD
Neostigmine—ABCB1—lung—chronic obstructive pulmonary disease	0.00127	0.0184	CbGeAlD
Neostigmine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.00123	0.00132	CcSEcCtD
Neostigmine—Syncope—Prednisone—chronic obstructive pulmonary disease	0.0012	0.00129	CcSEcCtD
Neostigmine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.00119	0.00128	CcSEcCtD
Neostigmine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.00117	0.00126	CcSEcCtD
Neostigmine—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.00116	0.00124	CcSEcCtD
Neostigmine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.00114	0.00122	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.00113	0.00121	CcSEcCtD
Neostigmine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.00111	0.00119	CcSEcCtD
Neostigmine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.00109	0.00117	CcSEcCtD
Neostigmine—Shock—Prednisone—chronic obstructive pulmonary disease	0.00107	0.00115	CcSEcCtD
Neostigmine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.00107	0.00115	CcSEcCtD
Neostigmine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.00106	0.00114	CcSEcCtD
Neostigmine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.00106	0.00114	CcSEcCtD
Neostigmine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.00105	0.00113	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000993	0.00107	CcSEcCtD
Neostigmine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000992	0.00106	CcSEcCtD
Neostigmine—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000986	0.00106	CcSEcCtD
Neostigmine—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000946	0.00102	CcSEcCtD
Neostigmine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000945	0.00101	CcSEcCtD
Neostigmine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.00094	0.00101	CcSEcCtD
Neostigmine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000891	0.000957	CcSEcCtD
Neostigmine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000891	0.000957	CcSEcCtD
Neostigmine—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000866	0.00093	CcSEcCtD
Neostigmine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000862	0.000925	CcSEcCtD
Neostigmine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000803	0.000862	CcSEcCtD
Neostigmine—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000782	0.00084	CcSEcCtD
Neostigmine—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000771	0.000828	CcSEcCtD
Neostigmine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000746	0.000801	CcSEcCtD
Neostigmine—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000721	0.000774	CcSEcCtD
Neostigmine—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000693	0.000744	CcSEcCtD
Neostigmine—Rash—Prednisone—chronic obstructive pulmonary disease	0.000687	0.000738	CcSEcCtD
Neostigmine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000687	0.000737	CcSEcCtD
Neostigmine—Headache—Prednisone—chronic obstructive pulmonary disease	0.000683	0.000733	CcSEcCtD
Neostigmine—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000647	0.000695	CcSEcCtD
